Research programme: cancer vaccine - Cantech

Drug Profile

Research programme: cancer vaccine - Cantech

Alternative Names: Immune-therapeutic protein; ITP

Latest Information Update: 28 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Canteck Pharma
  • Developer Cantech Holding
  • Class Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Cancer
  • Research Autoimmune disorders

Most Recent Events

  • 07 Jun 2016 Registered for Cancer in Mexico (unspecified route) before June 2016
  • 27 May 2016 Reve Technologies is now called Cantech Holding
  • 10 May 2016 Early research in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top